FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1444268565> ?p ?o ?g. }

• W1444268565 endingPage "165" @default.
• W1444268565 startingPage "157" @default.
• W1444268565 abstract "Melanoma lacks a clinically useful blood‐based biomarker of disease activity to help guide patient management. To determine whether measurements of circulating, cell‐free, tumor‐associated BRAFmutant and NRASmutant DNA (ctDNA) have a higher sensitivity than LDH to detect metastatic disease prior to treatment initiation and upon disease progression we studied patients with unresectable stage IIIC/IV metastatic melanoma receiving treatment with BRAF inhibitor therapy or immune checkpoint blockade and at least 3 plasma samples obtained during their treatment course. Levels of BRAFmutant and NRASmutant ctDNA were determined using droplet digital PCR (ddPCR) assays. Among patients with samples available prior to treatment initiation ctDNA and LDH levels were elevated in 12/15 (80%) and 6/20 (30%) (p = 0.006) patients respectively. In patients with RECIST scores <5 cm prior to treatment initiation, ctDNA levels were elevated in 5/7 (71%) patients compared to LDH which was elevated in 1/13 (8%) patients (p = 0.007). Among all disease progression events the modified bootstrapped sensitivities for ctDNA and LDH were 82% and 40% respectively, with a median difference in sensitivity of 42% (95% confidence interval, 27%–58%; P < 0.001). In addition, ctDNA levels were elevated in 13/16 (81%) instances of non‐RECIST disease progression, including 10/12 (83%) instances of new brain metastases. In comparison LDH was elevated 8/16 (50%) instances of non‐RECIST disease progression, including 6/12 (50%) instances of new brain metastases. Overall, ctDNA had a higher sensitivity than LDH to detect disease progression, including non‐RECIST progression events. ctDNA has the potential to be a useful biomarker for monitoring melanoma disease activity." @default.
• W1444268565 created "2016-06-24" @default.
• W1444268565 creator A5009234498 @default.
• W1444268565 creator A5011993587 @default.
• W1444268565 creator A5027693579 @default.
• W1444268565 creator A5036350640 @default.
• W1444268565 creator A5041152213 @default.
• W1444268565 creator A5052752001 @default.
• W1444268565 creator A5056507476 @default.
• W1444268565 creator A5065486178 @default.
• W1444268565 creator A5066269472 @default.
• W1444268565 creator A5066292518 @default.
• W1444268565 creator A5079891305 @default.
• W1444268565 creator A5080300349 @default.
• W1444268565 creator A5080635562 @default.
• W1444268565 date "2015-09-25" @default.
• W1444268565 modified "2023-10-10" @default.
• W1444268565 title "Sensitivity of plasma BRAF^mutantand NRAS^mutantcell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression" @default.
• W1444268565 cites W1995795575 @default.
• W1444268565 cites W2015438948 @default.
• W1444268565 cites W2024968315 @default.
• W1444268565 cites W2058390096 @default.
• W1444268565 cites W2092479048 @default.
• W1444268565 cites W2096387850 @default.
• W1444268565 cites W2097995306 @default.
• W1444268565 cites W2100158834 @default.
• W1444268565 cites W2118151336 @default.
• W1444268565 cites W2118863192 @default.
• W1444268565 cites W2121110176 @default.
• W1444268565 cites W2128035403 @default.
• W1444268565 cites W2128542677 @default.
• W1444268565 cites W2134471382 @default.
• W1444268565 cites W2140575188 @default.
• W1444268565 cites W2143163879 @default.
• W1444268565 cites W2156078931 @default.
• W1444268565 cites W2160834915 @default.
• W1444268565 cites W2167806838 @default.
• W1444268565 cites W2168143310 @default.
• W1444268565 cites W2169198176 @default.
• W1444268565 cites W2171237493 @default.
• W1444268565 cites W4235642752 @default.
• W1444268565 cites W745076224 @default.
• W1444268565 doi "https://doi.org/10.1016/j.molonc.2015.09.005" @default.
• W1444268565 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4695284" @default.
• W1444268565 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26440707" @default.
• W1444268565 hasPublicationYear "2015" @default.
• W1444268565 type Work @default.
• W1444268565 sameAs 1444268565 @default.
• W1444268565 citedByCount "58" @default.
• W1444268565 countsByYear W14442685652016 @default.
• W1444268565 countsByYear W14442685652017 @default.
• W1444268565 countsByYear W14442685652018 @default.
• W1444268565 countsByYear W14442685652019 @default.
• W1444268565 countsByYear W14442685652020 @default.
• W1444268565 countsByYear W14442685652021 @default.
• W1444268565 countsByYear W14442685652022 @default.
• W1444268565 countsByYear W14442685652023 @default.
• W1444268565 crossrefType "journal-article" @default.
• W1444268565 hasAuthorship W1444268565A5009234498 @default.
• W1444268565 hasAuthorship W1444268565A5011993587 @default.
• W1444268565 hasAuthorship W1444268565A5027693579 @default.
• W1444268565 hasAuthorship W1444268565A5036350640 @default.
• W1444268565 hasAuthorship W1444268565A5041152213 @default.
• W1444268565 hasAuthorship W1444268565A5052752001 @default.
• W1444268565 hasAuthorship W1444268565A5056507476 @default.
• W1444268565 hasAuthorship W1444268565A5065486178 @default.
• W1444268565 hasAuthorship W1444268565A5066269472 @default.
• W1444268565 hasAuthorship W1444268565A5066292518 @default.
• W1444268565 hasAuthorship W1444268565A5079891305 @default.
• W1444268565 hasAuthorship W1444268565A5080300349 @default.
• W1444268565 hasAuthorship W1444268565A5080635562 @default.
• W1444268565 hasBestOaLocation W14442685651 @default.
• W1444268565 hasConcept C121608353 @default.
• W1444268565 hasConcept C126322002 @default.
• W1444268565 hasConcept C141341695 @default.
• W1444268565 hasConcept C142724271 @default.
• W1444268565 hasConcept C143998085 @default.
• W1444268565 hasConcept C21790070 @default.
• W1444268565 hasConcept C2777658100 @default.
• W1444268565 hasConcept C2778822529 @default.
• W1444268565 hasConcept C2779134260 @default.
• W1444268565 hasConcept C2779984678 @default.
• W1444268565 hasConcept C2781187634 @default.
• W1444268565 hasConcept C2781197716 @default.
• W1444268565 hasConcept C44249647 @default.
• W1444268565 hasConcept C502942594 @default.
• W1444268565 hasConcept C526805850 @default.
• W1444268565 hasConcept C55493867 @default.
• W1444268565 hasConcept C71924100 @default.
• W1444268565 hasConcept C86803240 @default.
• W1444268565 hasConcept C90924648 @default.
• W1444268565 hasConceptScore W1444268565C121608353 @default.
• W1444268565 hasConceptScore W1444268565C126322002 @default.
• W1444268565 hasConceptScore W1444268565C141341695 @default.
• W1444268565 hasConceptScore W1444268565C142724271 @default.
• W1444268565 hasConceptScore W1444268565C143998085 @default.
• W1444268565 hasConceptScore W1444268565C21790070 @default.
• W1444268565 hasConceptScore W1444268565C2777658100 @default.

• next